Canine antibody libraries

IN604968BActive Publication Date: 2026-10-05MORFOZIS AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
IN202017001756
Authority / Receiving Office
IN · IN
Patent Type
Patents
Current Assignee / Owner
Priority Date
2017-06-22
Filing Date
2020-01-15
Publication Date
2026-10-05
Estimated Expiration
2038-06-21

AI Technical Summary

Technical Problem

There is a lack of fully synthetic canine antibody libraries with diverse VH/VL compositions that are suitable for biomedical research, and existing methods do not provide reliable libraries with predefined and advantageous biophysical properties such as high monomeric content and thermal stability.

Method used

The development of synthetic canine antibody libraries using germline sequences, specifically selecting VH and VL germline regions based on frequency and sequence similarity, and optimizing these libraries for high display rates, monomeric content, and thermal stability through the use of phage display and removal of unfavorable post-translational modification sites.

Benefits of technology

The resulting libraries exhibit high display rates, monomeric content, and thermal stability, enabling the isolation of antibodies with favorable biophysical properties, which are essential for therapeutic applications in canine medicine.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention provides synthetic canine antibody libraries, as well as polypeptides, nucleic acids, vectors, host cells and methods used in conjunction with these libraries. The present invention also provides antibodies isolated from such libraries.
Need to check novelty before this filing date? Find Prior Art

Description

The present invention relates to and provides canine libraries, such as synthetic antibody libraries which are suitable for selection of fully canine antibodies. The invention also relates to synthetic nucleic acid sequences which encode individual or collections of canine antibodies, i.e. nucleic acid sequences encoding canine antibody libraries. Methods for generating and using such libraries are provided. In particular, the invention relates to the preparation of a library of fully canine antibodies by the use of synthetic germline sequences to generate a library of fully canine antibodies having specific biophysical properties.Background of the InventionImmunoglobulins, such as antibodies, are of continued and increasing interest for the pharmaceutical industry. Since 2000, the therapeutic market for monoclonal antibodies has grown exponentially and in 2007, eight of the 20 best-selling biotechnology drugs in the U.S. were therapeutic monoclonal antibodies each having worldwide annual sales of more than 5 billion USD. Therapeutic antibodies improve the treatment of many diseases and increasingly improve the quality of lives of patients even with the most severe and challenging diseases.Companion animals such as dogs develop similar diseases than humans underlying similar or even the same biological mechanisms and disorders. As an example, lymphoma is the most common neoplasm of the canine hemolymphatic system. It represents approximately 4.5% of all canine neoplasms and 15% of all malignant neoplasms. Canine lymphoma (CL) is usually rapidly fatal, resulting in death within one to three months of diagnosis (Squire et al, 1973; Steven E. Crow, 2008). Furthermore, it is estimated that one in five adult dogs in the USA has arthritis and dogs have been used as models of human joint disease, e.g. for osteoarthritis, anterior cruciate ligament disruption and meniscal damage.Therefore therapeutic monoclonal antibodies not only provide a highly promising drug class for the treatment of humans but also for the treatment of dogs.There are already attempts to use antibodies for the treatment of dogs. Even prior to the U.S. Food and Drug Administration's (FDA) approval of the first monoclonal antibody for the treatment of human cancer, in 1992 the United States Department of Agriculture (USDA) had approved the monoclonal antibody MAb 231 for use in dogs with lymphoma. MAb 231 is a murine-derived monoclonal antibody which was generated using the hybridoma technology developed by Kohler and Milstein in 1975 and specifically binds the canine lymphoma cell line 17-71 (see e.g.: US5169775A). MAb 231 was demonstrated to bind tumor cells and not normal cells and was of the therapeutically desirable murine isotype IgG2a that mediates cell cytotoxicity.Meanwhile methods to "caninise" antibodies and therefore mimic canine antibodies are in use. For example, Gearing et al. (BMC Veterinary Research 2013, 9:226) discloses the generation of a "fully caninised" anti-NGF monoclonal antibody by using an algorithm that is based on expressed canine immunoglobulin sequences to convert an existing rat anti-NGF monoclonal antibody into a recombinant caninised anti-NGF mAb.To the inventors' knowledge, neither a fully synthetic canine antibody library nor any other reliable canine antibody library with a predefined and diverse VH / VL composition previously has been disclosed. Within the present invention, rational analysis of the naturally occurring canine antibody sequences and sophisticated design of the libraries, led to the first fully synthetic canine antibody libraries that are broadly useful for biomedical research. The members of the library were also selected for advantageous properties, such as a high monomeric content and a high thermal stability.As for the methods of screening the synthetic canine antibody libraries, display on phage, E. coli, yeast, or the like can be used. In the preferred phage display, for example, antibodies are presented as a fusion polypeptide on a bacteriophage surface protein. The antibody-displayed phage particles are brought into contact with a target molecule of interest (for example immobilized on a solid phase (e.g.: microtiter plate, magnetic bead etc.) or in solution), to thereby conduct an affinity selection. Phages expressing antibodies having affinity to the target molecule are selected, phages with antibodies that do not bind the target molecule are washed away during the selections round, commonly referred to as "(bio)-panning". In phage display, the antibody presented on the selected phages corresponds one-to-one to the gene coding the same, and therefore, the antibody of interest can be easily identified. Further, the gene encoding the antibody can be easily amplified, and therefore, phage display is widely used as method for screening and isolating antibodies from large libraries.Summary of the inventionSince immunoglobulin sequences encoded by canine germline sequences are expected not to be immunogenic in dogs, we searched for germline immunoglobulin sequences representing classes of the most abundant canine antibodies.According to Bao et al. (Veterinary Immunology and Immunopathology 137 (2010) 64– 75) the canine antibody VH gene repertoire includes 80 VH segments (of which 41 are functional and 39 are pseudogenes), 6 DH and 3 JH segments. The VH gene is formed by the combination of the different V, D and J gene segments from said VH gene repertoire and is joined by the addition or deletion of short coding sequences at the VD and VJ joints to increase the diversity of the antibodies. The VDJ recombination which occurs prior to the germinal center entry is not completely random but specific VH genes are used more frequently than others.In canine the 1-VH62 (Vs624) and the 1-VH44 (Vs635) were identified to be the most frequent used VH segments in splenic B cells, with an occurrence of 27% for 1-VH62 and 23,4% for 1-VH44 (Bao et al. 2010). All remaining VH were used with less than 11 % frequency. In canine three VH families (VH1, VH2 and VH3) exist of which the majority belong to the VH1 family, while 2-VH51, 2-VH64 and 2-VH66 belong to the VH2 family and 3-VH80 represents the only VH3 family member.The antibody light chains in canine are also based on variable regions encoded by V and J gene segments and a constant region encoded by kappa and lambda genes. Canis familiaris immunoglobulin lambda sequences can be grouped in four VL lambda chain families [V-I (GenBankAccession no. XM845300), V-II (GenBank Accession no. XM543519), V-III (GenBank Accession no. XM844188) and V-IV (GenBank Accession no. XM844237)]C. familiaris immunoglobulin kappa sequences, also can be grouped in four VL kappa chain families V-I (Gen Bank Accession no. XM849621), V-II (Gen Bank Accession no. XM844874), V-l 11 (Gen BankAccession no. XM849629) and V-IV (Gen Bank Accession no. XM849668) sequences (Braganza et al., Veterinary Immunology and Immunopathology 139 (2011) 27– 40). Dogs were found to express 90% lambda and only 10% of kappa light chains (Braganza et al., Veterinary Immunology and Immunopathology 139 (2011) 27–40). However, the distribution and arrangement of the specific light chains of canines as well the VH / VL combinations occurring in dogs are hardly characterized so far.Based on the distribution of the VH genes as described in the literature and sequence similarity analysis specific VH genes were selected for the synthetic canine antibody library. For the VL genes the information provided in Braganza et al., 2011 and a consensus sequence based on the 86 lambda light chain germline sequences and 29 kappa light chain germline sequences available on http: / / vgenerepertoire.org were used to select specific light chain germline sequences for the synthetic canine antibody library.We tested five representative canine VH germline sequences and six representative canine VL germline sequences (4 lambda VLs, 2 kappa VLs). Out of the 30 possible VH / VL combinations we identified 6 combinations which exhibited the following advantageous properties: (i) they showed a high display rate on the tip of filamentous phages in Fab-format, (ii) they are expressed in soluble form with a high monomeric content in Fab format and (iii) are expressed with a high monomeric content in IgG format.The selection of the frameworks was chosen to optimize the chance of obtaining antibodies which possess favorable biophysical properties and which are devoid of short comings of antibodies derived from synthetic libraries which have not undergone in-vivomaturation. Such favorable and desired biophysical properties for example include higher stability and a low tendency for aggregation as exemplified herein.For the six most favorable VH / VL combinations the L-CDR3 and the H-CDR3 regions were replaced by highly diversified L-CDR3 and H-CDR3 library cassettes, respectively, thereby achieving an overall library size of more than 5x109 members. Respective restriction sites were implemented to enable L-CDR3 and H-CDR3-library cassette insertion.In addition, unfavorable post-translational modification (PTM) sites were removed from specific germline sequences to further optimize expression and biophysical properties of the respective VH or VL genes and corresponding proteins.It is important to be aware of post-translational modifications that occur in antibody formulations for therapeutic applications. PTMs not necessarily take place in antibody samples produced for initial in vitro characterization, however PTMs might take place in antibody samples of high concentration and under long storage conditions, but also occur in vivo. Thereby, PTMs can interfere with antibody stability and / or homogeneity and might lead to loss of antibody functionality. Examples of PTMs include but are not limited to Oxidation (Met, Trp, His), Deamidation (Asn, Gin), Isomerization (Asp) or N-linked glycosylation (Asn).The present disclosure provides synthetic canine antibody libraries, preferably libraries comprising members of at least one germline VH1 region and at least one germline VL region.In one aspect, said libraries provided herein comprise members of at least two germline VH1 region and at least two germline VL regions.In one aspect, provided herein is a synthetic canine antibody library, wherein said library comprises members of at least one of the following germline VH1 regions: Vs618 (SEQ ID No.:4), Vs624 (SEQ ID No.:1) and Vs635 (SEQ ID No.:2).In one aspect, provided herein is a synthetic canine antibody library wherein said library comprises members of at least two of the following germline VH1 regions: Vs618 (SEQ ID No.:4), Vs624 (SEQ ID No.:1) and Vs635 (SEQ ID No.:2). In another aspect, provided herein is a synthetic canine antibody library wherein said library further comprises members of at least two germline VL regions.In one aspect, provided herein is a synthetic canine antibody library, wherein said library comprises at least one of the following germline VL regions: Vs236 (kappa) (SEQ ID No.:12), Vs323 (lambda) (SEQ ID No.:16) and Vs365 (lambda) (SEQ ID No.:13).In one embodiment of the present disclosure said germline VL regions are selected from the following germline VL regions: Vs236 (kappa) (SEQ ID No.:12), Vs323 (lambda) (SEQ ID No.:16) and Vs365 (lambda) (SEQ ID No.:13).In one aspect, provided herein is a synthetic canine antibody library wherein said library comprises at least two of the germline VH regions: Vs618 (SEQ ID No.:4), Vs624 (SEQ ID No.:1) and Vs635 (SEQ ID No.:2) and at least two of the following germline VL regions: Vs236 (kappa) (SEQ ID No.:12), Vs323 (lambda) (SEQ ID No.:16) and Vs365 (lambda) (SEQ ID No.:13).In another aspect, provided herein is a synthetic canine antibody library wherein said library comprises the germline VH regions: Vs618 (SEQ ID No.:4), Vs624 (SEQ ID No.:1) and Vs635 (SEQ ID No.:2) and the following germline VL regions: Vs236 (kappa) (SEQ ID No.:12), Vs323 (lambda) (SEQ ID No.:16) and Vs365 (lambda) (SEQ ID No.:13).In another aspect, provided herein is a synthetic canine antibody library wherein said library consists of at least one of the germline VH regions: Vs618 (SEQ ID No.:4), Vs624 (SEQ ID No.:1) and Vs635 (SEQ ID No.:2) and at least one of the following germline VL regions: Vs236 (kappa) (SEQ ID No.:12), Vs323 (lambda) (SEQ ID No.:16) and Vs365 (lambda) (SEQ ID No.:13).In another aspect, provided herein is a synthetic canine antibody library wherein said library consists of at least two of the germline VH regions: Vs618 (SEQ ID No.:4), Vs624 (SEQ ID No.:1) and Vs635 (SEQ ID No.:2) and at least two of the following germline VL regions: Vs236 (kappa) (SEQ ID No.:12), Vs323 (lambda) (SEQ ID No.:16) and Vs365 (lambda) (SEQ ID No.:13).In another aspect, provided herein is synthetic canine antibody library wherein said library consists of the germline VH regions: Vs618 (SEQ ID No.:4), Vs624 (SEQ ID No.:1) and Vs635 (SEQ ID No.:2) and the following germline VL regions: Vs236 (kappa) (SEQ ID No.:12), Vs323 (lambda) (SEQ ID No.:16) and Vs365 (lambda) (SEQ ID No.:13).In another aspect, provided herein is synthetic canine antibody library, wherein post-translational modification (PTM) sites are removed from one or more of the germline VH regions or the germline VL regions.In another aspect, provided herein is synthetic canine antibody library, wherein said library comprises the VH regions: Vs618 (SEQ ID No.:4), Vs624-PTM-low (SEQ ID No.:6) and Vs635-PTM-low (SEQ ID No.:7) and the VL regions: Vs236 (kappa) (SEQ ID No.:12), Vs323-PTM-low (lambda) (SEQ ID No.:18) and Vs365 (lambda) (SEQ ID No.:13).In another aspect, provided herein is synthetic canine antibody library, wherein said library comprises the VH / VL combinations of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs365 (lambda) (SEQ ID No.:13), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs365 (lambda) (SEQ ID No.:13) and the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs365 (lambda) (SEQ ID No.:13).In one aspect, provided herein is a synthetic canine antibody library wherein said library comprises members of at least two of the following germline VH1 regions: Vs618 (SEQ ID No.:4), Vs624 (SEQ ID No.:1), Vs628 (SEQ ID No.:5) and Vs635 (SEQ ID No.:2). in another aspect, provided herein is a synthetic canine antibody library wherein said library further comprises members of at least two germline VL regions.In one aspect, provided herein is a synthetic canine antibody library, wherein said library comprises at least one of the following germline VL regions: Vs236 (kappa) (SEQ ID No.:12), Vs321 (lambda) (SEQ ID No.: 14), Vs323 (lambda) (SEQ ID No.:16), Vs365 (lambda) (SEQ ID No.:13) and Vs843 (lambda) (SEQ ID No.:15).In one embodiment of the present disclosure said germline VL regions are selected from the following germline VL regions: Vs236 (kappa) (SEQ ID No.:12), Vs321 (lambda) (SEQ ID No.: 14), Vs323 (lambda) (SEQ ID No.:16), Vs365 (lambda) (SEQ ID No : 13) and Vs843 (lambda) (SEQ ID No.:15).In one aspect, provided herein is a synthetic canine antibody library wherein said library comprises at least two of the germline VH regions: Vs618 (SEQ ID No.:4), Vs624 (SEQ ID No.:1), Vs628 (SEQ ID No.:5) and Vs635 (SEQ ID No.:2) and at least two of the following germline VL regions: Vs236 (kappa) (SEQ ID No.:12), Vs321 (lambda) (SEQ ID No.: 14), Vs323 (lambda) (SEQ ID No.:16), Vs365 (lambda) (SEQ ID No.:13) and Vs843 (lambda) (SEQ ID No.:15).In another aspect, provided herein is a synthetic canine antibody library wherein said library comprises the germline VH regions: Vs618 (SEQ ID No.:4), Vs624 (SEQ ID No.:1), Vs628 (SEQ ID No.:5) and Vs635 (SEQ ID No.:2) and the following germline VL regions: Vs236 (kappa) (SEQ ID No.:12), Vs321 (lambda) (SEQ ID No.: 14), Vs323 (lambda) (SEQ ID No.:16), Vs365 (lambda) (SEQ ID No.:13) and Vs843 (lambda) (SEQ ID No.:15).In another aspect, provided herein is a synthetic canine antibody library wherein said library consists of at least one of the germline VH regions: Vs618 (SEQ ID No.:4), Vs624 (SEQ ID No.:1), Vs628 (SEQ ID No.:5) and Vs635 (SEQ ID No.:2) and at least one of the following germline VL regions: Vs236 (kappa) (SEQ ID No.:12), Vs321 (lambda) (SEQ ID No.: 14), Vs323 (lambda) (SEQ ID No.:16), Vs365 (lambda) (SEQ ID No.:13) and Vs843 (lambda) (SEQ ID No.:15).In another aspect, provided herein is a synthetic canine antibody library wherein said library consists of at least two of the germline VH regions: Vs618 (SEQ ID No.:4), Vs624 (SEQ ID No.:1), Vs628 (SEQ ID No.:5) and Vs635 (SEQ ID No.:2) and at least two of the following germline VL regions: Vs236 (kappa) (SEQ ID No.:12), Vs321 (lambda) (SEQ ID No.: 14), Vs323 (lambda) (SEQ ID No.:16), Vs365 (lambda) (SEQ ID No.:13) and Vs843 (lambda) (SEQ ID No.:15).In another aspect, provided herein is synthetic canine antibody library wherein said library consists of the germline VH regions: Vs618 (SEQ ID No.:4), Vs624 (SEQ ID No.:1), Vs628 (SEQ ID No.:5) and Vs635 (SEQ ID No.:2) and the following germline VL regions: Vs236 (kappa) (SEQ ID No.:12), Vs321 (lambda) (SEQ ID No.: 14), Vs323 (lambda) (SEQ ID No.:16), Vs365 (lambda) (SEQ ID No.:13) and Vs843 (lambda) (SEQ ID No.:15).In another aspect, provided herein is synthetic canine antibody library, wherein post-translational modification (PTM) sites are removed from one or more of the germline VH regions or the germline VL regions.In another aspect, provided herein is synthetic canine antibody library, wherein said library comprises the VH regions: Vs618 (SEQ ID No.:4), Vs624-PTM-low (SEQ ID No.:6), Vs628-PTM-low (SEQ ID No.:10) and Vs635-PTM-low (SEQ ID No.:7) and the VL regions: Vs236 (kappa) (SEQ ID No.:12), Vs321 (lambda) (SEQ ID No.:14), Vs323-PTM-low (lambda) (SEQ ID No.:18), Vs365 (lambda) (SEQ ID No.:13)and Vs843 (lambda) (SEQ ID No.:15).In another aspect, provided herein is synthetic canine antibody library, wherein said library comprises one or more of the following VH / VL combinations: the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL regionVs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs365 (lambda) (SEQ ID No.:13), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs365 (lambda) (SEQ ID No.:13) and the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7), the VL region Vs365 (lambda) (SEQ ID No.:13), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs843 (lambda) (SEQ ID No.:15), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs843 (lambda) (SEQ ID No.:15), and the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs843 (lambda) (SEQ ID No.:15), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No..6) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs321 (lambda) (SEQ ID No.: 14), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs321 (lambda) (SEQ ID No.:14), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs321 (lambda) (SEQ ID No.:14), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs628-PTM-low (SEQ ID No.:10) and the VL region VS236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs628-PTM-low (SEQ ID No.:10) and the VL region Vs365 (lambda) (SEQ ID No.:13), and the VH / VL combination of the VH1 region Vs628-PTM-low (SEQ ID No.:10) and the VL region Vs843 (lambda) (SEQ ID No.:15).In another aspect, provided herein is a synthetic canine antibody library, wherein at least50%, at least 60%, at least 70%, at least 80% or at least 90% of the antibodies or functional fragments comprise variable heavy chain and variable light chain combinations, wherein the framework regions of said variable heavy chain and variable light chain combinations comprises one or more of the VH / VL combinations disclosed herein.In another aspect, provided herein is a synthetic canine antibody library, wherein at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the antibodies or functional fragments comprise variable heavy chain and variable light chain combinations, wherein the framework regions of said variable heavy chain and variable light chain combinations comprise one or more of the following VH / VL combinations: the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs365 (lambda) (SEQ ID No.:13), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs365 (lambda) (SEQ ID No.:13) and the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7), the VL region Vs365 (lambda) (SEQ ID No.:13).In another aspect, provided herein is a synthetic canine antibody library, wherein at least50%, at least 60%, at least 70%, at least 80% or at least 90% of the antibodies or functional fragments comprise variable heavy chain and variable light chain combinations, wherein the framework regions of said variable heavy chain and variable light chain combinations consist of one or more of the following VH / VL combinations: the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs365 (lambda) (SEQ ID No.:13), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs365 (lambda) (SEQ ID No.:13) and the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7), the VL region Vs365 (lambda) (SEQ ID No.:13).In another aspect, provided herein is a synthetic canine antibody library, wherein at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the antibodies or functional fragments comprise variable heavy chain and variable light chain combinations, wherein the framework regions of said variable heavy chain and variable light chain combinations consist one or more of the VH / VL combinations disclosed herein.In another aspect, provided herein is a synthetic canine antibody library, wherein at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the antibodies or functional fragments comprise variable heavy chain and variable light chain combinations, wherein the framework regions of said variable heavy chain and variable light chain combinations comprise at least 2, at least 3, at least 4, at least 5, at least 6 of the following VH / VL combinations: the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs365 (lambda) (SEQ ID No.:13), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs365 (lambda) (SEQ ID No.:13) and the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7), the VL region Vs365 (lambda) (SEQ ID No.:13).In another aspect, provided herein is a synthetic canine antibody library, wherein at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the antibodies or functional fragments comprise variable heavy chain and variable light chain combinations, wherein the framework regions of said variable heavy chain and variable light chain combinations consist of at least 2, at least 3, at least 4, at least 5, at least 6 of the following VH / VL combinations: the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs365 (lambda) (SEQ ID No.:13), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs365 (lambda) (SEQ ID No.:13) and the VH / VLcombination of the VH1 region Vs635-PTM-low (SEQ ID No.:7), the VL region Vs365 (lambda) (SEQ ID No.:13).In another aspect, provided herein is a synthetic canine antibody library, wherein at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the antibodies or functional fragments comprise variable heavy chain and variable light chain combinations, wherein the framework regions of said variable heavy chain and variable light chain combinations consist of at least 2, at least 3, at least 4, at least 5, at least 6 of the VH / VL combinations disclosed herein.In another aspect, provided herein is a synthetic canine antibody library, wherein at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the antibodies or functional fragments comprise variable heavy chain and variable light chain combinations, wherein the framework regions of said variable heavy chain and variable light chain combinations consist one or more of the following VH / VL combinations: the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs236 (kappa) (SEQ ID No.: 12), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs236 (kappa) (SEQ ID No.: 12), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs365 (lambda) (SEQ ID No.:13), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs365 (lambda) (SEQ ID No.:13) and the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7), the VL region Vs365 (lambda) (SEQ ID No.:13), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs843 (lambda) (SEQ ID No.:15), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs843 (lambda) (SEQ ID No.:15), and the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs843 (lambda) (SEQ ID No.:15), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs321 (lambda) (SEQID No.:14), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs321 (lambda) (SEQ ID No.:14), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs321 (lambda) (SEQ ID No.:14), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs628-PTM-low (SEQ ID No.:10) and the VL region VS236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs628-PTM-low (SEQ ID No.:10) and the VL region Vs365 (lambda) (SEQ ID No.:13), and the VH / VL combination of the VH1 region Vs628-PTM-low (SEQ ID No.:10) and the VL region Vs843 (lambda) (SEQ ID No.:15).In another aspect, provided herein is a synthetic canine antibody library, wherein at least 50% of the antibodies or functional fragments comprise variable heavy chain and variable light chain combinations, wherein the framework regions of said variable heavy chain and variable light chain combinations comprise one or more of the following VH / VL combinations: the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs365 (lambda) (SEQ ID No.:13), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs365 (lambda) (SEQ ID No.:13) and the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7), the VL region Vs365 (lambda) (SEQ ID No.:13), the VHA / L combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs843 (lambda) (SEQ ID No.:15), the VHA / L combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs843 (lambda) (SEQ ID No.:15), and the VHA / L combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs843 (lambda) (SEQ ID No.:15), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs321 (lambda) (SEQ ID No.:14), the VHA / L combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs321 (lambda) (SEQ ID No.:14), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs321 (lambda) (SEQ ID No.:14), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs628-PTM-low (SEQ ID No.:10) and the VL region VS236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs628-PTM-low (SEQ ID No.:10) and the VL region Vs365 (lambda) (SEQ ID No.:13), and the VH / VL combination of the VH1 region Vs628-PTM-low (SEQ ID No.:10) and the VL region Vs843 (lambda) (SEQ ID No.:15).In another aspect, provided herein is a synthetic canine antibody library, wherein at least50%, at least 60%, at least 70%, at least 80% or at least 90% of the antibodies or functional fragments comprise variable heavy chain and variable light chain combinations, wherein the framework regions of said variable heavy chain and variable light chain combinations consist of at least 2, at least 3, at least 4, at least 5, at least 6, at least 8, at least 10, at least 12, at least 14, at least 16 of the following VH / VL combinations: the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs365 (lambda) (SEQ ID No.:13), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs365 (lambda) (SEQ ID No.:13) and the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7), the VL region Vs365 (lambda) (SEQ ID No.:13), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs843 (lambda) (SEQ ID No.:15), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs843 (lambda) (SEQ ID No.:15), and the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs843 (lambda) (SEQ ID No.:15), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs321 (lambda) (SEQID No.:14), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs321 (lambda) (SEQ ID No.:14), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs321 (lambda) (SEQ ID No.:14), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs628-PTM-low (SEQ ID No.: 10) and the VL region VS236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs628-PTM-low (SEQ ID No.:10) and the VL region Vs365 (lambda) (SEQ ID No.:13), and the VH / VL combination of the VH1 region Vs628-PTM-low (SEQ ID No.:10) and the VL region Vs843 (lambda) (SEQ ID No.:15).In another aspect, provided herein is a synthetic canine antibody library, wherein at least 50% of the antibodies or functional fragments comprise variable heavy chain and variable light chain combinations, wherein the framework regions of said variable heavy chain and variable light chain combinations consist of at least 2, at least 3, at least 4, at least 5, at least 6, at least 8, at least 10, at least 12, at least 14, at least 16 of the following VH / VL combinations: the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs365 (lambda) (SEQ ID No.:13), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs365 (lambda) (SEQ ID No.:13) and the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7), the VL region Vs365 (lambda) (SEQ ID No.: 13), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs843 (lambda) (SEQ ID No.:15), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs843 (lambda) (SEQ ID No.:15), and the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs843 (lambda) (SEQ ID No.: 15), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs618(SEQ ID No.:4) and the VL region Vs321 (lambda) (SEQ ID No.:14), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs321 (lambda) (SEQ ID No.:14), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs321 (lambda) (SEQ ID No.:14), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs628-PTM-low (SEQ ID No.:10) and the VL region VS236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs628-PTM-low (SEQ ID No.:10) and the VL region Vs365 (lambda) (SEQ ID No.:13), and the VH / VL combination of the VH1 region Vs628-PTM-low (SEQ ID No.:10) and the VL region Vs843 (lambda) (SEQ ID No.:15).In another aspect, provided herein is a synthetic canine antibody library, wherein at least 80% of the antibodies or functional fragments comprise variable heavy chain and variable light chain combinations, wherein the framework regions of said variable heavy chain and variable light chain combinations comprise one or more of the following VH / VL combinations: the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs236 (kappa) (SEQ ID No.: 12), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs365 (lambda) (SEQ ID No.:13), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs365 (lambda) (SEQ ID No.:13) and the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7), the VL region Vs365 (lambda) (SEQ ID No.:13), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs843 (lambda) (SEQ ID No.:15), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs843 (lambda) (SEQ ID No.:15), and the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs843 (lambda) (SEQ ID No.:15), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs321 (lambda) (SEQ ID No.:14), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs321 (lambda) (SEQ ID No.:14), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs321 (lambda) (SEQ ID No.:14), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs628-PTM-low (SEQ ID No.:10) and the VL region VS236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs628-PTM-low (SEQ ID No.:10) and the VL region Vs365 (lambda) (SEQ ID No.:13), and the VH / VL combination of the VH1 region Vs628-PTM-low (SEQ ID No.:10) and the VL region Vs843 (lambda) (SEQ ID No.:15).In another aspect, provided herein is a synthetic canine antibody library, wherein at least 50% of the antibodies or functional fragments comprise variable heavy chain and variable light chain combinations, wherein the framework regions of said variable heavy chain and variable light chain combinations consist of one or more of the following VH / VL combinations: the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs365 (lambda) (SEQ ID No.:13), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs365 (lambda) (SEQ ID No.:13) and the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7), the VL region Vs365 (lambda) (SEQ ID No.:13), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs843 (lambda) (SEQ ID No.:15), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs843 (lambda) (SEQ ID No.:15), and the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs843 (lambda) (SEQ ID No.:15), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs321 (lambda) (SEQ ID No.:14), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs321 (lambda) (SEQ ID No.:14), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs321 (lambda) (SEQ ID No.:14), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs628-PTM-low (SEQ ID No.:10) and the VL region VS236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs628-PTM-low (SEQ ID No.:10) and the VL region Vs365 (lambda) (SEQ ID No.:13), and the VH / VL combination of the VH1 region Vs628-PTM-low (SEQ ID No.:10) and the VL region Vs843 (lambda) (SEQ ID No.:15).In another aspect, provided herein is a synthetic canine antibody library, wherein at least80% of the antibodies or functional fragments comprise variable heavy chain and variable light chain combinations, wherein the framework regions of said variable heavy chain and variable light chain combinations consist of one or more of the following VH / VL combinations: the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs365 (lambda) (SEQ ID No.:13), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs365 (lambda) (SEQ ID No.:13) and the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7), the VL region Vs365 (lambda) (SEQ ID No.:13), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs843 (lambda) (SEQ ID No.:15), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs843 (lambda) (SEQ ID No.:15), and the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs843 (lambda) (SEQ ID No.: 15), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs321 (lambda) (SEQ ID No.:14), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs321 (lambda) (SEQ ID No.:14), the VH / VLcombination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs321 (lambda) (SEQ ID No.:14), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs628-PTM-low (SEQ ID No.:10) and the VL region VS236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs628-PTM-low (SEQ ID No.:10) and the VL region Vs365 (lambda) (SEQ ID No.:13), and the VH / VL combination of the VH1 region Vs628-PTM-low (SEQ ID No.:10) and the VL region Vs843 (lambda) (SEQ ID No.:15).In one aspect, provided herein is a synthetic canine antibody library, preferably such library comprising members of at least one germline VH1 region and / or at least two germline VL regions, wherein essentially all VH / VL combinations of said library are efficiently displayed in Fab format.In one aspect said VH / VL combinations of said library are displayed in Fab format, having a display rate of at least 0.5 Fab per phage.In one aspect, provided herein is a synthetic canine antibody library, preferably such library comprising members of at least one germline VH1 region and / or at least two germline VL regions, wherein essentially all VH / VL combinations are expressed in E. coli in Fab format. In one embodiment said VH / VL combinations expressed in E. coli in Fab format have a monomeric content of at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100%.In one aspect, provided herein is a synthetic canine antibody library, preferably such library comprising members of at least one germline VH1 region and / or at least two germline VL regions, wherein essentially all VH / VL combinations are expressed in a mammalian system in IgG format. In one embodiment said VH / VL combinations expressed in a mammalian system in IgG format have a monomeric content of at least 75%, 80%, 85%, 90%.95%, 96%, 97%, 98%, 99%, 100%.In one aspect, provided herein is a synthetic canine antibody library, preferably such library comprising members of at least one germline VH1 region and / or at least two germline VL regions, wherein essentially all VH / VL combinations are thermally stable.The present disclosure also provides collections of nucleic acid molecules encoding the antibodies of said synthetic canine antibody libraries.The present disclosure also provides vectors encoding said nucleic acid molecules.The present disclosure also provides recombinant host cells comprising said nucleic acid molecules or vectors.The present disclosure also provides methods to isolate antibodies specific for an antigen, said method comprising the steps of:(a) contacting the synthetic canine antibody libraries of the present disclosure with an antigen;(b) removing those members of the library which do not bind to (or are not specific for) the antigen;and(c) recovering those members of the library bound to (or specific for) the antigen.The present disclosure also provides antibodies isolated from a aforementioned libraries or aforementioned method.Brief Description of the DrawingsFigure 1The identity table analysis of 41 canine VH genes shows distance values for all possible sequence pairs for the sequences that are included in the alignment. Distance scores (i.e., 100 minus identity score) between sequence pairs are indicated. Identity scores betweensequence pairs are the percentage of identical residues among all ungapped positions between the pairs.Figure 2The identity table analysis of 29 canine Vkappa genes shows distance values for all possible sequence pairs for the sequences that are included in the alignment. Distance scores (i.e., 100 minus identity score) between sequence pairs are indicated. Identity scores between sequence pairs are the percentage of identical residues among all ungapped positions between the pairs.Figure 3The identity table analysis of 86 canine Vlambda genes shows distance values for all possible sequence pairs for the sequences that are included in the alignment. Distance scores (i.e., 100 minus identity score) between sequence pairs are indicated. Identity scores between sequence pairs are the percentage of identical residues among all ungapped positions between the pairs.Figure 4Western blot analysis of a subset of VH / VL constructs to evaluate Fab-display rates.Figure 5Densiometric analysis of the blot shown in Figure 4 indicating suitable display rates (typically, 0.5 to 2 Fabs / phage) for efficient phage display.Figure 630 VH / VL combinations were analyzed for relative Fab expression in bacterial cell lysates by ELISA where the expression level of each VH / VL pair was determined relative to the expression of a reference Fab control. Essentially all tested Fab VH / VL pairs showed a relative expression of at least 0.5 of the controls. Lambda clones had, on average, the highest relative Fab expression levels. Sample numbers are codified in Table 3.Figure 7Fab expression yields (indicated as bars; left axis) and monomer contents (indicated as dots; right axis) of 30 VH / VL combinations. Sample numbers are codified in Table 3.Figure 8Research-scale IgG expression yields (indicated as bars; left axis) and monomer contents (indicated as dots; right axis) of 30 VH / VL combinations. Sample numbers are codified in Table 3.Figure 9Essential parts of the phage display vector pCaDis including relevant unique restriction sites are shown.Figure 10Essential parts of the bacterial Fab expression vector pCaBx including relevant unique restriction sites are shown.Figure 11High quality and correctness of the canine antibody library as shown by the VH mastergene distribution as expected per composition of the library.Figure 12The designed amino acid distribution (left bar) in comparison to the obtained amino acids at the corresponding positions (right bar) in the library for an exemplary light chain CDR confirms an accurate and correct composition of the synthetic library.Figure 13The design of the CDR-H3 length distribution (white bars) in comparison to the obtained CDR-H3 length distribution (dark bars) after MiSeq NGS quality control of ~ 7.9 million sequences.Figure 14Dot Blot visualization of Fab screening result. Signal over background values of specific binding to eGFP is depicted on the x-axis (direct ELISA), results of the Fab expression are shown on the y-axis (signal over background in a Fab-capture ELISA). Shapes of the dots indicate the respective panning subcode.Detailed Description of the InventionUnless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which this invention pertains.The terms "about" or "approximately" in the context of numerical values and ranges refers to values or ranges that approximate or are close to the recited values or ranges such that the invention can perform as intended, such as having a desired number or percentage of sequence homology, as is apparent to the skilled person from the teachings contained herein. This is due, at least in part, to the varying culture conditions and the variability of biological systems. Thus, these terms encompass values beyond those resulting from systematic error. These terms make explicit what is implicit.All ranges set forth herein in the summary and description of the invention include all numbers or values thereabout or there between of the numbers of the range. The ranges of the invention expressly denominate and set forth all integers, decimals and fractional values in the range. The term "about" can be used to describe a range.The term "antibody" as used herein includes whole antibodies and any antigen binding fragment (i.e., "antigen-binding portion") or single chains thereof. A naturally occurring "antibody" is a glycoprotein comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region of an IgG, IgA or IgD antibody is comprised of three domains, CH1 , CH2 and CH3, whereas the heavy chain of an IgM and IgE antibody is comprised of four domains CH1, CH2, CH3, CH4. Each light chain is comprised of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region is comprised of one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is composed of three CDRs and four FRs arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. The extent of the framework region and CDRs have been precisely defined (see Kabat, 1991, J. Immunol., 147, 915-920.; Chothia & Lesk, 1987, J. Mol. Biol. 196: 901-917; Chothia et al., 1989, Nature 342: 877-883; Al-Lazikani et al., 1997, J. Mol. Biol. 273: 927-948). The framework regions of an antibody, that is, the combined framework regions of the constituent light and heavy chains, serves to position and align the CDRs, which are primarily responsible for binding to an antigen.

Claims

WE Claims1. A synthetic canine antibody library, wherein said library comprises members of at least one of the following germline VH1 regions: Vs618 (SEQ ID No.:4), Vs624 (SEQ ID No.:1), Vs628 (SEQ ID No.:5) and Vs635 (SEQ ID No.:2).

2. The library of any of the preceding claims, wherein said library comprises at least one of the following germline VL regions: Vs236 (kappa) (SEQ ID No.:12), Vs321 (lambda) (SEQ ID No.: 14), Vs323 (lambda) (SEQ ID No.:16), Vs365 (lambda) (SEQ ID No.:13) and Vs843 (lambda) (SEQ ID No.:15).

3. The library of any of the preceding claims, wherein post-translational modification (PTM) sites are removed from one or more of the germline VH regions or the germline VL regions.

4. The library of any of the preceding claims, wherein said library comprises the VH regions: Vs618 (SEQ ID No.:4), Vs624-PTM-low (SEQ ID No.:6) and Vs635-PTM-low (SEQ ID No.:7) and the VL regions: Vs236 (kappa) (SEQ ID No.:12), Vs323-PTM-low (lambda)(SEQ ID No.: 18) and Vs365 (lambda) (SEQ ID No.:13).

5. The library of any of the preceding claims, wherein said library comprises the VH regions: Vs618 (SEQ ID No..4), Vs624-PTM-low (SEQ ID No.:6), Vs628-PTM-low (SEQ ID Νο:10) and Vs635-PTM-low (SEQ ID No.:7) and the VL regions: Vs236 (kappa) (SEQ ID No.:12), Vs321 (lambda) (SEQ ID No.:14), Vs323-PTM-low (lambda) (SEQ ID No.:18), Vs365 (lambda) (SEQ ID No.:13) and Vs843 (lambda) (SEQ ID No.:15).

6. The library of any of the preceding claims, wherein said library comprises one or more of the following VH / VL combinations: the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs236 (kappa) (SEQ ID No.:12), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs618(SEQ ID No.:4) and the VL region Vs365 (lambda) (SEQ ID No.:13), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs365 (lambda) (SEQ ID No.:13),the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs365 (lambda) (SEQ ID No.:13), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs843 (lambda) (SEQ ID No.:15), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs843 (lambda) (SEQ ID No.:15), and the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs843 (lambda) (SEQ ID No.:15), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs323-PTM-low (lambda) (SEQ ID No.:18), the VH / VL combination of the VH1 region Vs618 (SEQ ID No.:4) and the VL region Vs321 (lambda) (SEQ ID No.:14), the VH / VL combination of the VH1 region Vs624-PTM-low (SEQ ID No.:6) and the VL region Vs321 (lambda) (SEQ ID No.:14), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs321 (lambda) (SEQ ID No.:14), the VH / VL combination of the VH1 region Vs635-PTM-low (SEQ ID No.:7) and the VL region Vs236 (kappa) (SEQ ID No.:12) the VH / VL combination of the VH1 region Vs628-PTM-low (SEQ ID No.:10) and the VL region VS236 (kappa) (SEQ ID No.: 12), the VH / VL combination of the VH1 region Vs628-PTM-low (SEQ ID No.:10) and the VL region Vs365 (lambda) (SEQ ID No.:13), and the VH / VL combination of the VH1 region Vs628-PTM-low (SEQ ID No.:10) and the VL region Vs843 (lambda) (SEQ ID No.:15).

7. The library of any of the preceding claims, wherein essentially all VH / VL combinations of said library are efficiently displayed at a display rate of at least 0.5 Fab per phage.

8. The library of any of the preceding claims, wherein essentially all VH / VL combinations have a monomeric content of at least 85% when expressed in E. coli in Fab format.

9. The library of any of the preceding claims, wherein essentially all VH / VL combinations have a monomeric content of at least 90% when expressed in a mammalian system in IgG format.

10. The library of any of the preceding claims, wherein all VH / VL combinations are thermally stable.

11. A collection of nucleic acid molecules encoding the library members of any of the preceding claims.

12. A vector encoding the nucleic acid molecules of claim 11.

13. A recombinant host cell comprising the nucleic acid molecules of claim 11 or the vector of claim 12.

14. A method to isolate an antibody specific for an antigen, said method comprising the steps of:(a) contacting the library of any one of claims 1-10 with an antigen;(b) removing those members of the library which do not bind to the antigen; and(c) recovering those members of the library bound to the antigen.

15. An antibody isolated from a library of any one of claims 1-10 or isolated by the method of claim 14.